760 related articles for article (PubMed ID: 33191450)
21. Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma.
Corrie PG; Qian W; Basu B; Valle JW; Falk S; Lwuji C; Wasan H; Palmer D; Scott-Brown M; Wadsley J; Arif S; Bridgewater J; Propper D; Gillmore R; Gopinathan A; Skells R; Bundi P; Brais R; Dalchau K; Bax L; Chhabra A; Machin A; Dayim A; McAdam K; Cummins S; Wall L; Ellis R; Anthoney A; Evans J; Ma YT; Isherwood C; Neesse A; Tuveson D; Jodrell DI
Br J Cancer; 2020 Jun; 122(12):1760-1768. PubMed ID: 32350413
[TBL] [Abstract][Full Text] [Related]
22. Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).
Rinaldi Y; Pointet AL; Khemissa Akouz F; Le Malicot K; Wahiba B; Louafi S; Gratet A; Miglianico L; Laharie H; Bouhier Leporrier K; Thirot Bidault A; Texereau P; Coriat R; Terrebonne E; Gouttebel MC; Malka D; Bachet JB; Lepage C; Taieb J;
Eur J Cancer; 2020 Sep; 136():25-34. PubMed ID: 32623182
[TBL] [Abstract][Full Text] [Related]
23. Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study.
Yalcin S; Dane F; Oksuzoglu B; Ozdemir NY; Isikdogan A; Ozkan M; Demirag GG; Coskun HS; Karabulut B; Evrensel T; Ustaoglu MA; Ozdemir F; Turna H; Yavuzsen T; Aykan F; Sevinc A; Akbulut H; Yuce D; Hayran M; Kilickap S
BMC Cancer; 2020 Mar; 20(1):259. PubMed ID: 32228512
[TBL] [Abstract][Full Text] [Related]
24. Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
Riedl JM; Posch F; Horvath L; Gantschnigg A; Renneberg F; Schwarzenbacher E; Moik F; Barth DA; Rossmann CH; Stotz M; Schaberl-Moser R; Pichler M; Stöger H; Greil R; Djanani A; Schlick K; Gerger A
Eur J Cancer; 2021 Jul; 151():3-13. PubMed ID: 33951545
[TBL] [Abstract][Full Text] [Related]
25. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma.
Van Cutsem E; Tempero MA; Sigal D; Oh DY; Fazio N; Macarulla T; Hitre E; Hammel P; Hendifar AE; Bates SE; Li CP; Hingorani SR; de la Fouchardiere C; Kasi A; Heinemann V; Maraveyas A; Bahary N; Layos L; Sahai V; Zheng L; Lacy J; Park JO; Portales F; Oberstein P; Wu W; Chondros D; Bullock AJ;
J Clin Oncol; 2020 Sep; 38(27):3185-3194. PubMed ID: 32706635
[TBL] [Abstract][Full Text] [Related]
26. Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma.
Weiss GJ; Blaydorn L; Beck J; Bornemann-Kolatzki K; Urnovitz H; Schütz E; Khemka V
Invest New Drugs; 2018 Feb; 36(1):96-102. PubMed ID: 29119276
[TBL] [Abstract][Full Text] [Related]
27. Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1).
Gao S; Zhu X; Shi X; Cao K; Bian Y; Jiang H; Wang K; Guo S; Zhang H; Jin G
Radiat Oncol; 2019 Mar; 14(1):52. PubMed ID: 30917842
[TBL] [Abstract][Full Text] [Related]
28. A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer.
Fukahori M; Miwa K; Murotani K; Naito Y; Ushijima T; Sakaue T; Tanaka T; Nagasu S; Suga H; Kakuma T; Okabe Y; Torimura T
Medicine (Baltimore); 2021 May; 100(20):e26052. PubMed ID: 34011119
[TBL] [Abstract][Full Text] [Related]
29. Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial.
Cascinu S; Berardi R; Bianco R; Bilancia D; Zaniboni A; Ferrari D; Mosconi S; Spallanzani A; Cavanna L; Leo S; Negri F; Beretta GD; Sobrero A; Banzi M; Morabito A; Bittoni A; Marciano R; Ferrara D; Noventa S; Piccirillo MC; Labianca R; Mosconi C; Casadei Gardini A; Gallo C; Perrone F
Eur J Cancer; 2021 May; 148():422-429. PubMed ID: 33812334
[TBL] [Abstract][Full Text] [Related]
30. Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE).
Kundranda M; Gracian AC; Zafar SF; Meiri E; Bendell J; Algül H; Rivera F; Ahn ER; Watkins D; Pelzer U; Charu V; Zalutskaya A; Kuesters G; Pipas JM; Santillana S; Askoxylakis V; Ko AH
Ann Oncol; 2020 Jan; 31(1):79-87. PubMed ID: 31912800
[TBL] [Abstract][Full Text] [Related]
31. Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2.
Macarulla T; Pazo-Cid R; Guillén-Ponce C; López R; Vera R; Reboredo M; Muñoz Martin A; Rivera F; Díaz Beveridge R; La Casta A; Martín Valadés J; Martínez-Galán J; Ales I; Sastre J; Perea S; Hidalgo M
J Clin Oncol; 2019 Jan; 37(3):230-238. PubMed ID: 30523758
[TBL] [Abstract][Full Text] [Related]
32. Interstitial lung disease in advanced pancreatic ductal adenocarcinoma patients treated with gemcitabine and nab-paclitaxel combination therapy: a retrospective analysis.
Irie H; Suzuki R; Takagi T; Sugimoto M; Konno N; Sato Y; Hikichi T; Nakamura J; Hashimoto M; Ohira H
Cancer Chemother Pharmacol; 2020 Mar; 85(3):517-523. PubMed ID: 31691078
[TBL] [Abstract][Full Text] [Related]
33. Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional study.
Prager GW; Oehler L; Gerger A; Mlineritsch B; Andel J; Petzer A; Wilthoner K; Sliwa T; Pichler P; Winder T; Heibl S; Gruenberger B; Laengle F; Hubmann E; Korger M; Pecherstorfer M; Djanani A; Neumann HJ; Philipp-Abbrederis K; Wöll E; Trondl R; Arnold-Schrauf C; Eisterer W
Eur J Cancer; 2021 Jan; 143():101-112. PubMed ID: 33296830
[TBL] [Abstract][Full Text] [Related]
34. Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment.
Petrillo A; Pappalardo A; Pompella L; Tirino G; Calabrese F; Laterza MM; Caterino M; Ventriglia A; Orditura M; Conzo G; Molino C; Ciardiello F; Biglietto M; De Vita F
Med Oncol; 2019 Aug; 36(10):83. PubMed ID: 31444639
[TBL] [Abstract][Full Text] [Related]
35. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641
[TBL] [Abstract][Full Text] [Related]
36. Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-GS/GA-rP2, CSGO-HBP-015).
Yamada D; Kobayashi S; Takahashi H; Akita H; Yamada T; Asaoka T; Shimizu J; Takeda Y; Yokoyama S; Tsujie M; Tomokuni A; Tanemura M; Morimoto O; Murakami M; Kim Y; Nakahira S; Hama N; Sugimoto K; Hashimoto K; Doki Y; Eguchi H
Trials; 2021 Aug; 22(1):568. PubMed ID: 34446057
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma.
Zong Y; Peng Z; Wang X; Lu M; Shen L; Zhou J
Cancer Manag Res; 2020; 12():12657-12666. PubMed ID: 33328763
[TBL] [Abstract][Full Text] [Related]
38. Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma.
O'Reilly EM; Barone D; Mahalingam D; Bekaii-Saab T; Shao SH; Wolf J; Rosano M; Krause S; Richards DA; Yu KH; Roach JM; Flaherty KT; Ryan DP
Eur J Cancer; 2020 Jun; 132():112-121. PubMed ID: 32361265
[TBL] [Abstract][Full Text] [Related]
39.
Korn RL; Von Hoff DD; Borad MJ; Renschler MF; McGovern D; Curtis Bay R; Ramanathan RK
Cancer Imaging; 2017 Aug; 17(1):23. PubMed ID: 28774338
[TBL] [Abstract][Full Text] [Related]
40. Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.
Pointet AL; Tougeron D; Pernot S; Pozet A; Béchade D; Trouilloud I; Lourenco N; Hautefeuille V; Locher C; Williet N; Desrame J; Artru P; Soularue E; Le Roy B; Taieb J
Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):295-301. PubMed ID: 31607641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
